Post-Vax Clot Case Supports Angiomax Use

May 5, 2021

Medpage Today

Bivalirudin (Angiomax) worked for one of the very rare cases of blood clots with low platelets after vaccination against COVID-19, researchers reported.

The 40-year-old woman presented with a headache on the same day that the CDC and FDA hit pause on use of the Johnson & Johnson vaccine over risk of what's being dubbed vaccine-induced thrombotic thrombocytopenia (VITT) or thrombosis with thrombocytopenia syndrome (TTS).

She developed a headache, sinus pressure, myalgias, and sore throat with tonsillar exudate on day 5 post-vaccination but had no risk factors for clotting, stated R. Todd Clark, MD, MBA, of the University of Colorado School of Medicine in Aurora, and colleagues in the Annals of Emergency Medicine case report.

Click here to read the full article.

Read more In the News

In the News Public Education Research